Perbandingan Mortalitas Kardiak, Reinfark Dan Stroke Serta Efek Perdarahan Antara Heparin, Enoxaparin Dan Fondaparinux Pada Infark Miokard Akut ST Elevasi Tanpa Reperfusi Dini
DAFTAR PUSTAKA
ACSM Coronary Artery Disease Risk Factor Thresholds. 2008. Diunduh dari
http://www.acefitness.org/pdfs/ACSM-CAD-Risk-Factor-Chart.pdf.
Diakses 3 Mei 2013
Acang N. 2006. “Pemakaian dan pemantauan obat-obat antitrombosis.” Buku Ajar
Ilmu Penyakit Dalam. Edisi ke-4. Jakarta ; Pusat Penerbitan Departemen
Ilmu Penyakit Dalam FK UI
Andersen HR, Nielsen TT, Rasmussen K, dkk. A comparison of coronary
angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl
J Med . 2003;349:733-42.
Antmann E, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowzki Z, dkk.
Enoxaparin versus unfraction heparin with fibrinolysis for ST-elevation
myocardial infarction. New Engl J Med. 2006;354;1477-88
Antmann EM, Braunwald E. 2008. “ST elevation myocardial infarction :
Pathology, pathophysiology and clinical feature.” Braunwald’s Heart
Disease, a textbook of cardiovascular . Edisi ke-8. Philadelphia : Saunders
Elsevier
Badimon JJ, Badimon L, Ibanez B. 2011. “Coronary thrombosis : local and
systemic factors : introduction.” Hurst’s the Heart. Edisi ke-13. New York
; McGraw-Hill
Bauer K. New anticoagulants. Hematology. 2006;15:450-456
Bender JR, Russel KS, Rosenfeld LE, Chaundry S. 2011. “Coronary artery
disease.” Oxford American handbook of Cardiology. Edisi pertama. New
York : Oxford University Press
Bonaca MP, Steg PG, Feldman LJ, Canales JF, Ferguson JJ, Wallentin L, dkk.
Antithrombotics in acute coronary syndromes. J Am Coll Cardiol .
2009;54:969-84
Cannon CP, Fuster V. 2001. “Thrombogenesis, antithrombotic and thrombolytic
therapy.” Hurst’s the Heart. Edisi ke-10. New York : McGraw-Hill
Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT, Drozda DJ, dkk.
ACCF/AHA key data elements and definitions for measuring the clinical
management and outcomes of patients with acute coronary syndromes and
coronary artery disease. J Am Coll Cardiol. 2013;61(9):1-40
Universitas Sumatera Utara
Cheng S, Morrow DA, Sloan S, Antmann EM, Sabatine MS. Predictors of initial
non theraupetic anticoagulation with unfraction heparin in ST segment
elevation myocardial infarction. Circulation. 2009;119:1195-1202
Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, dkk. The
safety and efficacy of the subcutaneous Enoxaparin versus placebo in the
treatment of acute ST segment elevation myocardial infarction patients
ineligible for reperfusion (TETAMI). J Am Coll Cardiol. 2003;42:1348-56
Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, dkk.
Prospective evaluation of clinical outcomes after acute ST-elevation
myocardial infarction in patients who are ineligible for reperfusion
therapy: Preliminary results from the TETAMI registry and randomized
trial. Circulation. 2003;108(III):III-14-III-21)
Cohen M, Gensini GF, Maritz F. The role of gender and other factors as
predictors of not receiving reperfusion therapy and of outcome in ST
segment elevation myocardial infarction. J Thromb Thrombolysis.
2005;19: 155-61
Cohen M, Boaiangiu C, Abidi M. Therapy for ST segment myocardial infarction
patients who present late or are in eligible for reperfusion therapy. J Am
Coll Cardiol. 2010;55:1895-1906
Dahlan MS. 2011. “Uji hipotesis komparatif variabel numerik lebih dari dua
kelompok.” Statistik untuk kedokteran dan kesehatan. Edisi ke-5. Jakarta :
Salemba Medika.
Dahlan MS. 2012. “Analisis survival Coxx Regression model stratifikasi (asumsi
proportional hazard tidak terpenuhi).” Analisis survival : Dasar-dasar
teori dan aplikasi. Edisi pertama. Jakarta: Epidemiologi Indonesia
Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;
357: 2482-94
Dellinger RP, Levy MM, Bion J, Parker MM, Jaeschke R, Reinhard K, dkk.
Surviving sepsis campaign : International guidelines for management of
severe sepsis and septic shock: 2008. Critical Care Med. 2008; 10:1-48
De Caterina, Husted S, Wallentin R, Agnelli G, Bachmann F, Baigent C.
Anticoagulant in heart disease : Current status and perspectives. Eur Heart
J . 2007;28:885-888
Eagle KA, Goodman SG, Avezum A, Bunday A, Sullivan CM, Lopez Sendon J.
Practice variation and missed oppoortunities for reperfusion in ST segment
Universitas Sumatera Utara
elevation myocardial infarction-findings from the Global Registry of Acute
Coronary Events (GRACE). Lancet. 2002;359:373-377
Eagle KA, Nallamothu BK, Mehta RH, Granger CB, Steg PG, Van de Werf P,
dkk. Trends in acute reperfusion therapy for ST-segment elevation
myocardial infarction from 1999 to 2006: we are getting better but we have
got a long way to go. Eur Heart J . 2008;29:607-618
Eikelboom JW, Weitz JI. Anticoagulation for ST-segment elevation myocardial
infarction. Circulation. 2009;119:1186-1188
Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and
high risk plaque : Part I : evolving concepts. J Am Coll Cardiol.
2005;46:937-954
Furie B, Furie BC. Mechanism of thrombus formation. N Engl J Med. 2008; 359:
938-49
Gawaz M. The evolving science of atherothrombosis disease. Eur Heart J .
2008;10: 14-17
GG Turpie A. Fondaparinux in the management of patients with ST elevation
acute myocardial infarction. Vascular Health and Risk Management.
2006;2(4):371-378
GG Turpie A. Selective factor Xa inhibiton with Fondaparinux : from concept to
clinical benefit. Eur Heart J . 2008;10C:C1-C7
Gharacholau SM, Alexander KP, Chen AY, Wang TY, Melloni C, Gibler B, dkk.
Implications and reasons for the lack use of reperfusion therapy in patients
with STEMI. Findings from the CRUSADE initiative. Am Heart J. 2010;
159 (5) ; 1-7
Goodman SG, Menon V, Cannon CP, Steg G, Ohman M, Harrington RA, dkk.
Acute ST Segment myocardial infarction. American College of Chest
Physicians Evidence-based clinical practice guidelines. Chest.
2008;133:708S-705S.
Gogo PB, Dauerman HL, Sobel BE. 2010.“Reperfusion therapies for acute ST
segment myocardial infarction”. Cardiac Intensive Care. Edisi ke-2.
Philadelphia : Saunders Elsevier.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J
Med. 2005;352:1685-95
Hanna B, Glancy DL, Saucedo JF. Antiplatelet and anticoagulant therapies in
acute coronary syndromes. Cardiovasc Drugs Ther . 2010;24:61-70
Universitas Sumatera Utara
Hirsh J, Bauer KA, Donalti MB, Gould M, Samama MM, Weitz JI. Parenteral
anticoagulant : American College of Chest Physicians evidence based
clinical practice guidelines. Chest.2008;133:141S-159S
Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy :
Heparin. Circulation. 2001;103;2994-3018
Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD. Early
revascularization in acute myocardial infarction complicated by
cardiogenic shock. N Engl J Med. 1999; 341(9): 1-10
Hoffman M. 2010. “Regulation of hemostasis and thrombosis.” Cardiac
Intensive Care. Edisi ke-2. Philadelphia: Saunders Elsevier
Karlsberg RP, Tcheng JE, Boris JR, Buxton AE, Dove JT, Fonarow GC, dkk.
ACCF/AHA 2011 Key data elements and definitions of a base
cardiovascular vocabulary for electronic health records. J Am Coll Cardiol.
2011;58(2):202-222
Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous
thrombolytic therapy for acute myocardial infarction : A quantitative
review of 23 randomised trials. Lancet. 2003;361:13-20
Kumar A, Cannon CP. Acute coronary syndrome, diagnosis and management.
Mayo Clin Proc. 2009;84(10):917-938
Kumar A, Kar S, Fay WP. Thrombosis, physical activity, and acute coronary
syndromes. 2011. J Appl Physiol ;111: 599–605
Kleinschmid KC. Epidemiology and pathophysiology of acute coronary
syndrome. Adv Stud Med. 2006;6(6B):S477-S482
Libby P. Current concepts of the pathogenesis of the acute coronary syndrome.
Circulation . 2001;104:365-372
Libby P, Theroux P. Pathophysiology of coronary arteri disease. Circulation .
2005;111:3481-3488
Lopez Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H.
Expert consensus document on angiotensin converting enzyme inhibitors
in cardiovascular disease. Eur Heart J . 2004;25:1462-1463
Lopez Sendon J, Swedberg K, Mcmurray J, Tamargo J, Maggioni AP, Dargie H.
Expert consensus document on beta adrenergic receptor blockers. Eur
Heart J . 2004;25:1346-1347
Universitas Sumatera Utara
Madiono B, Moeslichan MZ S, Budiman I, Purwanto SH. 1995. “Perkiraan besar
sampel.” Dasar -dasar metodologi penelitian klinis. Edisi pertama.
Jakarta:Binarupa Aksara
McCann CJ, Menown IB. New anticoagulant strategies in ST elevation
myocardial infarction. Trials and clinical implications. Vascular Health
and Risks Management. 2008;4(2):305-313
McKee PA, Castell WP, McNamara PM, Kannel WB. The natural history of
congestive heart failure: the Framingham Study. N Engl J Med. 1971:285
Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Fillipatos G, dkk. The
second Euro Heart survey on acute coronary syndromes: characteristis,
treatment and outcome of patients with ACS in Europe and Mediteranean
Basin in 2004. Eur Heart J. 2006; 27: 22852293
Murphy SA, Gibson CM, Morrow DA, Van de Werf F, Menown IB, Goodman
SG. Efficacy and safety of the low molecular weight heparin Enoxaparin
compared with unfractionated heparin across the acute coronary syndrome
spectrum : a meta-analysis. Eur Heart J . 2007;28:2077-2086
Mukhtar Z. 2011. “Statistika kedokteran dan uji hipotesis.” Desain penelitian
klinis dan statistika kedokteran. Edisi pertama. Medan : USU Press
Newby LK, Harrington RA, Bhapkar MV, Van de Werf F, Hochman JS, Granger
CB, dkk. An automated strategy for bedside APTT determination and
unfraction heparin infusion adjustman in acute coronary syndrome :
insights from PARAGON A study, Abstract. Journal of Thrombosis and
Thrombolysis. 2004;14(1):33-42
National Cholesterol Education Program (NCEP). Expert panel on detection,
evaluation and treatment of high blood cholesterol in adult (Adult
treatment panel III). Circulation. 2002;106:3143
Nutesco E, Racine E. Traditional versus Modern Anticoagulant Strategies :
Summaries of the Literature. Am J Health Syst Pharm. 2002; 59(6)
Notoatmodjo S, penyunting. 2005. “Teknik pengambilan sampel.” Metodologi
penelitian kesehatan. Edisi revisi. Jakarta : Reneka Cipta
Oesman F, Setiabudy RD. 2007. “Fisiologi hemostasis dan fibrinolisis.”
Hemostasis dan trombosis. Edisi ke-3. Jakarta : Balai penerbit FK UI
Oldgren J, Wallentin L, Afzal R, Bassand JP, Buday A, Chrolavicius S, dkk
Effects of Fondaparinux in patients with ST-segment elevation acute
Universitas Sumatera Utara
myocardial infarction not receiving reperfusion treatment. Eur Heart J .
2008;29:315-323
Patel JV, Chambers CV, Gomella LG. Hematuria : Hematuria and evaluation for
the primary care physician. The Canadian Journal of Urology.
2008;15(supplement-1): 56-62
Rao SV, O’Grady K, Pieper KS, et al. A comparison of the clinical impact of
bleeding measured by two different classifications among patients with
acute coronary syndromes. J Am Coll Cardiol. 2006;47:809–16
Rubolli A, Capeccchi A, Di Pasquale G. Utilizing enoxaparin in the management
of STEMI. Vascular Health and Risk Management. 2007;3(50):691-700
Rupprecht HJ, Blank R. Clinical pharmacology of direct and indirect factor Xa
inhibitor, review. Drugs. 2010; 16 :2156-2158
Roe MT, Parsons LS, Pollack CV Jr, Canto JG, Barron HV, Every NR, dkk.
Quality of care by classification of myocardial infarction: treatment
patterns for ST-segment elevation vs Non-ST-segment elevation. Arch
Intern med. 2005;165:1630-1636
Rogers WJ, Canto JG, Lambrew CT, Tiefenburn AJ, Kinkaid B, Shoultd DA.
Temporal trends in the treatment of over 1.5 million patients with
myocardial infarction in the US from 1990 through 1999. The national
registry of myocardial infarction 1,2 and 3. J Am Coll Cardiol.
2000;36:2056-63
Rosen AB, gelfand AV. 2009. “Pathophysiology of acute coronary syndrome.”
Management of acute coronary syndrome. Edisi pertama. Toronto : John
Wiley&Sons
Samama MM, Gerotziafas GT. Newer anticoagulants in 2009. J Thromb
Thrombolysis. 2010;29:92-104
Schiele F. Fondaparinux and acute coronary syndrome ; update on the OASIS 56. Vascular Health and Risk Management. 2010:6 179–187
Steg PG, James SK, Atar D, Badano LP, Borger, badano LP, dkk. ESC guidelines
for the management of acute myocardial infarction in patients presenting
with ST segment elevation. Eur Heart J. 2012;10:1-51
Takii T, Yasuda S, Takahashi J, Ito K, Shiba N, Shirato K, dkk. Trends in acute
myocardial infarction incidence and mortality over 30 years in Japan :
report from the MIYAGI-AMI registry study. Circ J . 2010;74: 93-100
Universitas Sumatera Utara
Thygensen K, Alpert JS, White HD. Universal definition of myocardial infarction.
Eur Heart J . 2007;28:2525-2538
Van de Werf F, Bax J, Betriu A, Blomstorm-Lundgvista C, Crea F, Falk V dkk.
Management of acute myocardial infarction in patients presenting with
persistent ST segmen elevation, the task force on the management of ST
segment elevation acute myocardial infarction of European Society of
Cardiology. Eur Heart J . 2008; 29 : 2909-2945
Wienbergen H, Zeymer U. Management of acute coronary syndrome with
fondaparinux. Vascular Health and Risk Management. 2007:3(3) 321–329
WHO.
Cardiovascular
disease.
2013.
Diunduh
dari:http://www.who.int/entity/mediacentre/factsheets/fs317/en/index.html.
Diakses 14 April 2013
Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in
the incidence and outcomes of acute myocardial infarction. N Engl J Med.
2010;362:2155-65
Yusuf S. Effects of Repivarin, a low molecular weight heparin, on mortality,
reinfarction, and strokes in patients with acute myocardial infarction
presenting with ST segmen elevation. JAMA. 2005;29:427-436
Yusuf S. Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, dkk. Effects
of Fondaparinux on mortality and reinfarction in patients with acute ST
segmen elevation myocardial infarction : the OASIS 6 randomized clinical
trial. JAMA . 2006;295:1519-1530
Zeymer U, Gitt AK, Junger C. Clopidogrel in addition to Aspirin reduces in
hospital major cardiac and cerebrovascular events in unselected patients
with acute ST segment elevation myocardial infarction. Thromb Haemost.
2008;99;155-60
Universitas Sumatera Utara
ACSM Coronary Artery Disease Risk Factor Thresholds. 2008. Diunduh dari
http://www.acefitness.org/pdfs/ACSM-CAD-Risk-Factor-Chart.pdf.
Diakses 3 Mei 2013
Acang N. 2006. “Pemakaian dan pemantauan obat-obat antitrombosis.” Buku Ajar
Ilmu Penyakit Dalam. Edisi ke-4. Jakarta ; Pusat Penerbitan Departemen
Ilmu Penyakit Dalam FK UI
Andersen HR, Nielsen TT, Rasmussen K, dkk. A comparison of coronary
angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl
J Med . 2003;349:733-42.
Antmann E, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowzki Z, dkk.
Enoxaparin versus unfraction heparin with fibrinolysis for ST-elevation
myocardial infarction. New Engl J Med. 2006;354;1477-88
Antmann EM, Braunwald E. 2008. “ST elevation myocardial infarction :
Pathology, pathophysiology and clinical feature.” Braunwald’s Heart
Disease, a textbook of cardiovascular . Edisi ke-8. Philadelphia : Saunders
Elsevier
Badimon JJ, Badimon L, Ibanez B. 2011. “Coronary thrombosis : local and
systemic factors : introduction.” Hurst’s the Heart. Edisi ke-13. New York
; McGraw-Hill
Bauer K. New anticoagulants. Hematology. 2006;15:450-456
Bender JR, Russel KS, Rosenfeld LE, Chaundry S. 2011. “Coronary artery
disease.” Oxford American handbook of Cardiology. Edisi pertama. New
York : Oxford University Press
Bonaca MP, Steg PG, Feldman LJ, Canales JF, Ferguson JJ, Wallentin L, dkk.
Antithrombotics in acute coronary syndromes. J Am Coll Cardiol .
2009;54:969-84
Cannon CP, Fuster V. 2001. “Thrombogenesis, antithrombotic and thrombolytic
therapy.” Hurst’s the Heart. Edisi ke-10. New York : McGraw-Hill
Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT, Drozda DJ, dkk.
ACCF/AHA key data elements and definitions for measuring the clinical
management and outcomes of patients with acute coronary syndromes and
coronary artery disease. J Am Coll Cardiol. 2013;61(9):1-40
Universitas Sumatera Utara
Cheng S, Morrow DA, Sloan S, Antmann EM, Sabatine MS. Predictors of initial
non theraupetic anticoagulation with unfraction heparin in ST segment
elevation myocardial infarction. Circulation. 2009;119:1195-1202
Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, dkk. The
safety and efficacy of the subcutaneous Enoxaparin versus placebo in the
treatment of acute ST segment elevation myocardial infarction patients
ineligible for reperfusion (TETAMI). J Am Coll Cardiol. 2003;42:1348-56
Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, dkk.
Prospective evaluation of clinical outcomes after acute ST-elevation
myocardial infarction in patients who are ineligible for reperfusion
therapy: Preliminary results from the TETAMI registry and randomized
trial. Circulation. 2003;108(III):III-14-III-21)
Cohen M, Gensini GF, Maritz F. The role of gender and other factors as
predictors of not receiving reperfusion therapy and of outcome in ST
segment elevation myocardial infarction. J Thromb Thrombolysis.
2005;19: 155-61
Cohen M, Boaiangiu C, Abidi M. Therapy for ST segment myocardial infarction
patients who present late or are in eligible for reperfusion therapy. J Am
Coll Cardiol. 2010;55:1895-1906
Dahlan MS. 2011. “Uji hipotesis komparatif variabel numerik lebih dari dua
kelompok.” Statistik untuk kedokteran dan kesehatan. Edisi ke-5. Jakarta :
Salemba Medika.
Dahlan MS. 2012. “Analisis survival Coxx Regression model stratifikasi (asumsi
proportional hazard tidak terpenuhi).” Analisis survival : Dasar-dasar
teori dan aplikasi. Edisi pertama. Jakarta: Epidemiologi Indonesia
Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;
357: 2482-94
Dellinger RP, Levy MM, Bion J, Parker MM, Jaeschke R, Reinhard K, dkk.
Surviving sepsis campaign : International guidelines for management of
severe sepsis and septic shock: 2008. Critical Care Med. 2008; 10:1-48
De Caterina, Husted S, Wallentin R, Agnelli G, Bachmann F, Baigent C.
Anticoagulant in heart disease : Current status and perspectives. Eur Heart
J . 2007;28:885-888
Eagle KA, Goodman SG, Avezum A, Bunday A, Sullivan CM, Lopez Sendon J.
Practice variation and missed oppoortunities for reperfusion in ST segment
Universitas Sumatera Utara
elevation myocardial infarction-findings from the Global Registry of Acute
Coronary Events (GRACE). Lancet. 2002;359:373-377
Eagle KA, Nallamothu BK, Mehta RH, Granger CB, Steg PG, Van de Werf P,
dkk. Trends in acute reperfusion therapy for ST-segment elevation
myocardial infarction from 1999 to 2006: we are getting better but we have
got a long way to go. Eur Heart J . 2008;29:607-618
Eikelboom JW, Weitz JI. Anticoagulation for ST-segment elevation myocardial
infarction. Circulation. 2009;119:1186-1188
Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and
high risk plaque : Part I : evolving concepts. J Am Coll Cardiol.
2005;46:937-954
Furie B, Furie BC. Mechanism of thrombus formation. N Engl J Med. 2008; 359:
938-49
Gawaz M. The evolving science of atherothrombosis disease. Eur Heart J .
2008;10: 14-17
GG Turpie A. Fondaparinux in the management of patients with ST elevation
acute myocardial infarction. Vascular Health and Risk Management.
2006;2(4):371-378
GG Turpie A. Selective factor Xa inhibiton with Fondaparinux : from concept to
clinical benefit. Eur Heart J . 2008;10C:C1-C7
Gharacholau SM, Alexander KP, Chen AY, Wang TY, Melloni C, Gibler B, dkk.
Implications and reasons for the lack use of reperfusion therapy in patients
with STEMI. Findings from the CRUSADE initiative. Am Heart J. 2010;
159 (5) ; 1-7
Goodman SG, Menon V, Cannon CP, Steg G, Ohman M, Harrington RA, dkk.
Acute ST Segment myocardial infarction. American College of Chest
Physicians Evidence-based clinical practice guidelines. Chest.
2008;133:708S-705S.
Gogo PB, Dauerman HL, Sobel BE. 2010.“Reperfusion therapies for acute ST
segment myocardial infarction”. Cardiac Intensive Care. Edisi ke-2.
Philadelphia : Saunders Elsevier.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J
Med. 2005;352:1685-95
Hanna B, Glancy DL, Saucedo JF. Antiplatelet and anticoagulant therapies in
acute coronary syndromes. Cardiovasc Drugs Ther . 2010;24:61-70
Universitas Sumatera Utara
Hirsh J, Bauer KA, Donalti MB, Gould M, Samama MM, Weitz JI. Parenteral
anticoagulant : American College of Chest Physicians evidence based
clinical practice guidelines. Chest.2008;133:141S-159S
Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy :
Heparin. Circulation. 2001;103;2994-3018
Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD. Early
revascularization in acute myocardial infarction complicated by
cardiogenic shock. N Engl J Med. 1999; 341(9): 1-10
Hoffman M. 2010. “Regulation of hemostasis and thrombosis.” Cardiac
Intensive Care. Edisi ke-2. Philadelphia: Saunders Elsevier
Karlsberg RP, Tcheng JE, Boris JR, Buxton AE, Dove JT, Fonarow GC, dkk.
ACCF/AHA 2011 Key data elements and definitions of a base
cardiovascular vocabulary for electronic health records. J Am Coll Cardiol.
2011;58(2):202-222
Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous
thrombolytic therapy for acute myocardial infarction : A quantitative
review of 23 randomised trials. Lancet. 2003;361:13-20
Kumar A, Cannon CP. Acute coronary syndrome, diagnosis and management.
Mayo Clin Proc. 2009;84(10):917-938
Kumar A, Kar S, Fay WP. Thrombosis, physical activity, and acute coronary
syndromes. 2011. J Appl Physiol ;111: 599–605
Kleinschmid KC. Epidemiology and pathophysiology of acute coronary
syndrome. Adv Stud Med. 2006;6(6B):S477-S482
Libby P. Current concepts of the pathogenesis of the acute coronary syndrome.
Circulation . 2001;104:365-372
Libby P, Theroux P. Pathophysiology of coronary arteri disease. Circulation .
2005;111:3481-3488
Lopez Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H.
Expert consensus document on angiotensin converting enzyme inhibitors
in cardiovascular disease. Eur Heart J . 2004;25:1462-1463
Lopez Sendon J, Swedberg K, Mcmurray J, Tamargo J, Maggioni AP, Dargie H.
Expert consensus document on beta adrenergic receptor blockers. Eur
Heart J . 2004;25:1346-1347
Universitas Sumatera Utara
Madiono B, Moeslichan MZ S, Budiman I, Purwanto SH. 1995. “Perkiraan besar
sampel.” Dasar -dasar metodologi penelitian klinis. Edisi pertama.
Jakarta:Binarupa Aksara
McCann CJ, Menown IB. New anticoagulant strategies in ST elevation
myocardial infarction. Trials and clinical implications. Vascular Health
and Risks Management. 2008;4(2):305-313
McKee PA, Castell WP, McNamara PM, Kannel WB. The natural history of
congestive heart failure: the Framingham Study. N Engl J Med. 1971:285
Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Fillipatos G, dkk. The
second Euro Heart survey on acute coronary syndromes: characteristis,
treatment and outcome of patients with ACS in Europe and Mediteranean
Basin in 2004. Eur Heart J. 2006; 27: 22852293
Murphy SA, Gibson CM, Morrow DA, Van de Werf F, Menown IB, Goodman
SG. Efficacy and safety of the low molecular weight heparin Enoxaparin
compared with unfractionated heparin across the acute coronary syndrome
spectrum : a meta-analysis. Eur Heart J . 2007;28:2077-2086
Mukhtar Z. 2011. “Statistika kedokteran dan uji hipotesis.” Desain penelitian
klinis dan statistika kedokteran. Edisi pertama. Medan : USU Press
Newby LK, Harrington RA, Bhapkar MV, Van de Werf F, Hochman JS, Granger
CB, dkk. An automated strategy for bedside APTT determination and
unfraction heparin infusion adjustman in acute coronary syndrome :
insights from PARAGON A study, Abstract. Journal of Thrombosis and
Thrombolysis. 2004;14(1):33-42
National Cholesterol Education Program (NCEP). Expert panel on detection,
evaluation and treatment of high blood cholesterol in adult (Adult
treatment panel III). Circulation. 2002;106:3143
Nutesco E, Racine E. Traditional versus Modern Anticoagulant Strategies :
Summaries of the Literature. Am J Health Syst Pharm. 2002; 59(6)
Notoatmodjo S, penyunting. 2005. “Teknik pengambilan sampel.” Metodologi
penelitian kesehatan. Edisi revisi. Jakarta : Reneka Cipta
Oesman F, Setiabudy RD. 2007. “Fisiologi hemostasis dan fibrinolisis.”
Hemostasis dan trombosis. Edisi ke-3. Jakarta : Balai penerbit FK UI
Oldgren J, Wallentin L, Afzal R, Bassand JP, Buday A, Chrolavicius S, dkk
Effects of Fondaparinux in patients with ST-segment elevation acute
Universitas Sumatera Utara
myocardial infarction not receiving reperfusion treatment. Eur Heart J .
2008;29:315-323
Patel JV, Chambers CV, Gomella LG. Hematuria : Hematuria and evaluation for
the primary care physician. The Canadian Journal of Urology.
2008;15(supplement-1): 56-62
Rao SV, O’Grady K, Pieper KS, et al. A comparison of the clinical impact of
bleeding measured by two different classifications among patients with
acute coronary syndromes. J Am Coll Cardiol. 2006;47:809–16
Rubolli A, Capeccchi A, Di Pasquale G. Utilizing enoxaparin in the management
of STEMI. Vascular Health and Risk Management. 2007;3(50):691-700
Rupprecht HJ, Blank R. Clinical pharmacology of direct and indirect factor Xa
inhibitor, review. Drugs. 2010; 16 :2156-2158
Roe MT, Parsons LS, Pollack CV Jr, Canto JG, Barron HV, Every NR, dkk.
Quality of care by classification of myocardial infarction: treatment
patterns for ST-segment elevation vs Non-ST-segment elevation. Arch
Intern med. 2005;165:1630-1636
Rogers WJ, Canto JG, Lambrew CT, Tiefenburn AJ, Kinkaid B, Shoultd DA.
Temporal trends in the treatment of over 1.5 million patients with
myocardial infarction in the US from 1990 through 1999. The national
registry of myocardial infarction 1,2 and 3. J Am Coll Cardiol.
2000;36:2056-63
Rosen AB, gelfand AV. 2009. “Pathophysiology of acute coronary syndrome.”
Management of acute coronary syndrome. Edisi pertama. Toronto : John
Wiley&Sons
Samama MM, Gerotziafas GT. Newer anticoagulants in 2009. J Thromb
Thrombolysis. 2010;29:92-104
Schiele F. Fondaparinux and acute coronary syndrome ; update on the OASIS 56. Vascular Health and Risk Management. 2010:6 179–187
Steg PG, James SK, Atar D, Badano LP, Borger, badano LP, dkk. ESC guidelines
for the management of acute myocardial infarction in patients presenting
with ST segment elevation. Eur Heart J. 2012;10:1-51
Takii T, Yasuda S, Takahashi J, Ito K, Shiba N, Shirato K, dkk. Trends in acute
myocardial infarction incidence and mortality over 30 years in Japan :
report from the MIYAGI-AMI registry study. Circ J . 2010;74: 93-100
Universitas Sumatera Utara
Thygensen K, Alpert JS, White HD. Universal definition of myocardial infarction.
Eur Heart J . 2007;28:2525-2538
Van de Werf F, Bax J, Betriu A, Blomstorm-Lundgvista C, Crea F, Falk V dkk.
Management of acute myocardial infarction in patients presenting with
persistent ST segmen elevation, the task force on the management of ST
segment elevation acute myocardial infarction of European Society of
Cardiology. Eur Heart J . 2008; 29 : 2909-2945
Wienbergen H, Zeymer U. Management of acute coronary syndrome with
fondaparinux. Vascular Health and Risk Management. 2007:3(3) 321–329
WHO.
Cardiovascular
disease.
2013.
Diunduh
dari:http://www.who.int/entity/mediacentre/factsheets/fs317/en/index.html.
Diakses 14 April 2013
Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in
the incidence and outcomes of acute myocardial infarction. N Engl J Med.
2010;362:2155-65
Yusuf S. Effects of Repivarin, a low molecular weight heparin, on mortality,
reinfarction, and strokes in patients with acute myocardial infarction
presenting with ST segmen elevation. JAMA. 2005;29:427-436
Yusuf S. Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, dkk. Effects
of Fondaparinux on mortality and reinfarction in patients with acute ST
segmen elevation myocardial infarction : the OASIS 6 randomized clinical
trial. JAMA . 2006;295:1519-1530
Zeymer U, Gitt AK, Junger C. Clopidogrel in addition to Aspirin reduces in
hospital major cardiac and cerebrovascular events in unselected patients
with acute ST segment elevation myocardial infarction. Thromb Haemost.
2008;99;155-60
Universitas Sumatera Utara